Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc

Bullboard Posts

Post by pericles1on Dec 19, 2013 11:59am

173 Views

Post# 22022823

Adam Feurstein

He basically said that because IMUC failed NWBO will fail too. I do not have much respect for him his analysis is shallow in my opinion, but I do not have as much confidence as I had before IMUC's results. I just don't understand how 80 to 90% of the phase I result in IMUC's trial was just an illusion, The main way to cherry pick patients is age that's the one factor that seems to make a big difference for survival. The younger the better. I'm holding only need a couple months better than IMUC's two months and we will be in clover.

Bullboard Posts

AI companies to invest in